Henry Schein (HSIC) Receiving Somewhat Favorable Media Coverage, Analysis Finds

Media stories about Henry Schein (NASDAQ:HSIC) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Henry Schein earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.9931293719759 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the headlines that may have impacted Accern’s scoring:

Shares of Henry Schein (NASDAQ:HSIC) traded up $1.54 during mid-day trading on Monday, reaching $74.84. The company had a trading volume of 1,045,507 shares, compared to its average volume of 1,296,067. The company has a market cap of $11,750.00, a price-to-earnings ratio of 21.57, a P/E/G ratio of 1.91 and a beta of 0.99. Henry Schein has a twelve month low of $65.28 and a twelve month high of $93.50. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Monday, November 6th. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The business had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the company earned $0.84 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. sell-side analysts anticipate that Henry Schein will post 3.6 earnings per share for the current fiscal year.

Henry Schein declared that its board has authorized a share repurchase program on Monday, September 18th that permits the company to buyback $400.00 million in outstanding shares. This buyback authorization permits the company to repurchase up to 6.3% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Several brokerages have recently commented on HSIC. Jefferies Group reissued a “hold” rating and set a $88.50 price target on shares of Henry Schein in a report on Thursday, September 28th. Evercore ISI started coverage on Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective for the company. Leerink Swann reaffirmed a “market perform” rating and issued a $77.00 price objective (down from $87.50) on shares of Henry Schein in a report on Tuesday, November 7th. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Finally, Stephens started coverage on Henry Schein in a report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $84.23.

In related news, Director Barry J. Alperin sold 5,796 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the transaction, the director now directly owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.19% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/15/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-henry-schein-hsic-share-price.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply